N
Google TrendMICHAEL OLISE (500+) — Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:michael olise500+bank of america fine1000+club brugge200+rb leipzig200+anthony gordon500+mid atlantic ridge earthquakes500+montez sweat2000+rob lowe1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves Sacituzumab" (30 stories)

Top Headline Story

FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
Lead StoryOncLivegeneral
Jun 24

FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOYk9ibVRpR2JkbGVPWUU0ZnRQSl96Y1lXYVdNZWtkcWFMSTFPMGp3Q2d3UFo0Z2trcHZUWWJubmZ4d0tvQ1BYbm9sN1VUZDcxcWhwcFlEaGd0UnFuOFV2OVJBRmswRzVSd3hsRGswWWFWSjhHS0tydXBGcnZ1QUZndzZCREtMZnZ2dkZGaFdIb05PWGpxWjdGclVfVVhaRWd5SzA2NjFPWFY1V09VNlRvaWE0UTlUSU5XTEExcEE1eFVHZmdEZzVJSnkwMA?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+25m ago

michael olise

Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay

Filter stories
1000+25m ago

bank of america fine

Bank of America fined $1.2 billion over money-laundering violations

Filter stories
200+25m ago

club brugge

LIVE: Dan toch 1-1! Club laat zich na penalty Tresoldi te makkelijk vangen, Lautaro zorgt voor gelijkmaker

Filter stories
200+25m ago

rb leipzig

Nach 6:0 in der Liga: Demichelis erwartet anderes Kaliber

Filter stories

Search Results for "FDA Approves Sacituzumab"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment
Targeted Oncologygeneral

FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNek4yRDJuMHhDUGc2b0NBbDNDWEZaOE11ckVpZDdRRl9oanhYUmVrT2cyc1RGdHZIVXlLUEsycnJEOWJ6eV9GZndvZTFuRlJ2MFg2Uk5MYlJhUzBjeUlfUmZxOHd0dWE4dmZfNi14OU5ZTXRkOTBrMjRqYktWLWhMaXFtQjR4ZzhlVHJEVjVMdHRpUW5uUEtoWEMtUmdZdw?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer
Oncology News Centralgeneral

FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPdklTTW55OEI5MFpvNV9GbEllWDlBMHNiYUYxX08yTVgwNGwySlBjS1NlZkZuR3JnZ0xzOHBzeUhNWExMeVl6YkxabF9ZWTRrTzlYdmpHdTg0NnJXRVFDcjdYcm40V1J4RlhGclo0d1RHam1TM1BtSlVrX1g1UXd1VG5fcnVicXhZd2dhbkEwN01lcFJXM2dmclo4Q0hxdVM0MXB6NjhCTGwxYXk1Wm1PN29SM1ZsR3M3aEE?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
The American Journal of Managed Caregeneral

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNVjVEN1JpUWlWVGVpdk1GVTFIdGtZeFZQTlU1bV9QRnBNSDUxWThKVE1WREdOblBKYVFkSmJROTEtMUxPWVNCcUVhWjdsQjZqZXJLeUdRNk9oRm1nd0ZXWVo0ei1rUW1jSWNaamtNNWJabkE3WDgtUi1SQXZBdjZzbmhPRURtbTBRRGRlYWFGamhhb2gxeXM1UDY3ZFB1TlIwRTJGYm8zaXZNYV9yQUR2bmpGUHNDa09DWlVIRTJR?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer
Oncology Nursing Newsgeneral

FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNZURwNjIza2J5aENMbDhhSEhLWDZHd2RDWTdGclJpX3NtcjJwa2p6Y1BtTWNJRXVnVlpBNWRBdGxISXFMZnZJeFNTOE1tQUZJdWtub2R0bFU4UDJJRjc5WTFvdnJlMW1RMzRFaUprSWZST1lQSUwxaDFLN2o5V1FNTTJMQndGbG85N2hlQUpVRXpUaTN3Wi1ReXRzUGFXSkhIUkZDRjk0NFpqbnhabktsRFpMb3JJbEVKSkR1Mw?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
CancerNetworkgeneral

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPWmJIMlljU2F0WTZ4ZFc0MUpwbUVMRnFfS3FzRXg0c0ZqUDdUMFQ4Vkg0bzFNQjZaTldYUWl6MnBIbnNFXzZFblF3N2NtNTUwVU9jYzRKclBxbmxGano0U0htczUzdXlSNERVbFFCUmk2T1dPaXd1dndTR3ctbXhhcmlScnBVbTVIcEU1ak5ycnZKVlhFS1FFRGstT3REZzJpTGJXQ3VObw?oc=5" target="_blank">Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer
Pharmacy Timesgeneral

FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOd0VwcFFyM2VoUjFnQ1RsU0NLYzFxYjFuT3cxeTdsZlJxbjBBbGFESVgwd2hRc3FlRVZxWWNPUXlmOWp4MlZLaUtfVnFGN1ZyWkNTOC1WYWdGWmFvcE9qWnJtbVJvY0NuYjlsSTFNWmd3clEyMTBRX2lzdUdaOHAxTkFIVjVRb3hTZUtoSGk3V3RxSGVDOURfYWdqV2tsVWN0WU9pQ1JZMlhxcmNxRkdEWDVVU250bzZTNEdzY1ljQkRzdlEycG9DekliN0NSWkQyNGc?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC
Oncodailygeneral

FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTFBidGIxVVpXRTRjTXFQRmdUWkpOekJfX3JIQzZSX1lOTUpZTlRpMFJoNDRwelRBOGk0aEUtWUdBUjRERG5lMFNpUWlrdUNpbFhKN29GWlZHdnhTa0FUSktaVkc0NFlweDJFRF9qX3l3dEs3cUxDRktEazBOSlo1YVk?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
Cure Todaygeneral

FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPaV9nYnRJOGVqVXVhUGYyWHJHazRYZjBTNXRQVkJMdHJLaHVsU0VtQzFNY2xoRWZzMjBiSzltWDJtLUo4bFRvTUQ5MGZORFQ4ZnliYmNZQTRucXJ2WHhQVTQ5ZVBEd0RBMExjV1RYRE1Ca0MtSTVMeHpIQ1UtcUFrODhTSXhWam9IeWpzbkM3OE1IUFdGWTA5Vzl4dlh3Um5wMFJPX1Rjd3F5Q3FCLUd5Z2NYdXpPUQ?oc=5" target="_blank">FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
Pharmaceutical Executivegeneral

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNSTdQMlFETGlFa1RCQ292MVFIR2V4eVNQS2tld1d0ZlJjSHNNYXdnZDRoNlRtNzJqNjF3cjRlcmdkSjFwdF9Oa1RJclJuSXhfMU9DbTNkRlg2dDNRSmU0Ylp2anBMZVV2VGdYTk1aYnpBZUFYWDEwQ2tnT3A5WlFnTEpQLTlJcFhPay1seFcyUDd2RGs1RE41dWo3Y2k2SWRkSmx3SkFhcGNrNDNi?oc=5" target="_blank">FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves Two New Treatments For Metastatic TNBC
Breast Cancer.orggeneral

FDA Approves Two New Treatments For Metastatic TNBC

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE94RlRfOTUtTklveXB5U0FQSTZSV0VMVUhBQ0pYODdQcjFGZ3pFTk9mUVFkeTNmVVZLb2VhcUw5NG96cFJobmxmUHFMV0tKQzNON0JWRDZUd1VlaWRvYWJIdTYwN01VSVl3U2dNZmpZWQ?oc=5" target="_blank">FDA Approves Two New Treatments For Metastatic TNBC</a>  <font color="#6f6f6f">Breast Cancer.org</font>

Read Full StoryMore like this
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciencesgeneral

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNUHlYa3R3c0ZFMkVvYWFOaTVLLVFXSC10TDI4SHJhMWVuN0dOVVZ4RmlvS3VKRkwtY2tCSkJ5Rnk0R2J6dktpT29lWEdMbWZpeUdzdTNuUm5rVlhkbW42amdKNWt0ZWdtUkpaU001ZVRmZkFKaUFjOUpheWVIa3hLbVhWTmsxR2hqN0lLY3YwUWdIbExKMEFkRFlUb19WazhYbmxJTlc1eHVtTEtPOFZjUWs5YnJDakUxMnVSd1dFNTZBZVZqRlMxT3VvVUhmeXhIUk5TUEpwVDhUMEI5cG5JTzBmZ3NPc3pCVWg1NVpLVVM4Zw?oc=5" target="_blank">U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Gilead Sciences</font>

Read Full StoryMore like this
First-Line Trodelvy Regimens Approved for Triple-Negative Breast Cancer
Medical Professionals Referencegeneral

First-Line Trodelvy Regimens Approved for Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNSTVUaTdxRWdXOENmMDhoZjFPQ3pwT3pRYjhVREU4UFJaMmV4Y3Y1UHJObm02ZWxYa1c2OVJnTWZ4RWxOcVBnWS1xWGUzQnU3UEJYdXcyeFVEWGhIaVlkQmg2dFZYLTdzVi1iMVFfODktaXQwLWZNOFFSdElqTlhwQmtBMTZlZDBvdFZzYVNn?oc=5" target="_blank">First-Line Trodelvy Regimens Approved for Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Medical Professionals Reference</font>

Read Full StoryMore like this
Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic Triple-Negative Breast Cancer
BioPharm Internationalgeneral

Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxORGlRSkJQRTFqSkN0Q19HV2NVTnNUaTA0THBPUi01THExZnQzdTg2SXB2ajZHdmx1MG1tUVNNbU4tdGE3UC1rcW9sQXdTYlJ5dDZ3R0pmVVZSRkJfYWZYYS1VcGZlWGJEdm8yMEUtNm93Q01ralJ1ZE5XMENDR01YandtMGtNZXBOajVMdjE5NHhDN21XWkU1aE1oWTd5RHZiNmtONjF1MHdfUkFlVGltSXpfbEc1Zw?oc=5" target="_blank">Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data Show Benefit Extending Past Initial Progression
Onco'Zinegeneral

FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data Show Benefit Extending Past Initial Progression

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPUkZtUk5nN3p2WjBWb2J1T3dLV2QzWFMzcTZBSkJSQTB4U0gwVHNxYzk1bHRuaWprdUVGZ3BUNEZwX1dnRXRWLU9qNHpWM2hWaTJTX212OTVpVFBzczRGVWdIQlVnREZOOXRweDgtamNWMjh5MXZadjItek5nZGh1RVI5WHNNN2VYangzMW5UWk5ka2RwTURDcXktQ0JjdWN1N3ZhTjNsV080b3V6U1BCalpXa1c3Vm9LelJBUHVlcmF1RDhYNkpXcWdsbk44RkVGRm5aYVRBNVdaaHlaQl9wTWd1QnJXTzc1UHZmc1pIMDBYN2JpVmRNV2JhT0NCU1VlS0E?oc=5" target="_blank">FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data Show Benefit Extending Past Initial Progression</a>  <font color="#6f6f6f">Onco'Zine</font>

Read Full StoryMore like this
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC
OncLiveworld

European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQQWtabEV3NTBXU1VmMFlBT0dkVFNwcXRTdWhHTGJKMXBnS0JNdWlUWUNwVFFxSGpMeENEeEZ2dFNfTTNZNVc4VzI3ZGk5UEo4VDV6eW5rSENwQkNkMHAwY2hyWDVMb2Fzek9UQ2Jtb2Z3dFpqWTNsR21Ra3l3bHVucWtpMTFxYThVUGNPc0F0ck9zMjI5N3FGb2p1QmJULUc3YzZvalpEaUNMQ3FFX2pPQzl5d1ROU2hpOGJQajVGWkZzQQ?oc=5" target="_blank">European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approvals for Metastatic TNBC: 2 New Options Explained
Oncodailytech

FDA Approvals for Metastatic TNBC: 2 New Options Explained

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE02M0h2dkxvVHhUTFc2NUFxZjdFdGFFWFhyUVVsU2RIWENSUE14aWVDR3F1SkVPNUFzblBvYkU4UkxXazc3cjNfTzZPRmdnVWllNFVDNGRQUFBiME85NGxiSVFDSkZhVzVtV1hfSGxnc2l3anc?oc=5" target="_blank">FDA Approvals for Metastatic TNBC: 2 New Options Explained</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
OncLivegeneral

Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSmFCS2JCZGZvMlB4aURjSzhacUpwYWR6cFJUSXVfVEl6TDNWZ2JCbk1fb1hjbk9JZjdjaVhnWXhoMVhwWjE3NmxkWTFjVnhIM3BFX2ZoNTdCZGRRanByNU9CS0FyNzhFZGlxRTFSMW8zSkc3Nk5MNWdPdm1BODVOVVpGWF9abVBMWFpuQ0wwY25KQmZyX1BrZUhpZG1MVGNqUnZLeFBVQzRmMjktenNHVzlFQm5xZGhnZXZQTHgyR1g?oc=5" target="_blank">Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Flashback: Breast Cancer Decisions and News From June 2026
OncLiveworld

FDA Flashback: Breast Cancer Decisions and News From June 2026

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPdzVUWXFQcVZQRmRHdFpLQzIwZ3hNVmg4ZzFQSS05d3FnOGQ3ck5Lc2daelA5TlNsZ2VuSmFjSjVLSEpqajVWNk9jdkpoOWhTQUlrM05JUHZ4X1laZ2laSTc2d2ptQk9wa1lQalZFTmpYaF83bEFBMHN2dmRscWVWYjRqckhiMVdkQnV2eExSbTZTcE5J?oc=5" target="_blank">FDA Flashback: Breast Cancer Decisions and News From June 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC
OncLivetech

Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOcmU3NkhmcGRPcmpTQUUxdXVBVXRXUHh6dmVtTUJ6VG80dEphcEJEYWdTNENRLXhjMUlqejh5R252STNBRm5YV1JoXy1qRkRQZFM0NUZ4ejRQVGx6bURvMTNjY0xPS0ZxbjhLaU4yOWR6cGI5Sy1OanRyRVpiTXRQMHl2bW9LVk1hOWZlWkZXS2pwTlhLdm1fRmNfSk9INXFOSUNvSnI0R0JmZTZWamttWXljd21rWGZTalE?oc=5" target="_blank">Sacituzumab Govitecan With/Without Pembrolizumab Aims to Fill Gap in Treatment-Naive TNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC
OncLivegeneral

CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQQWpzLW5LSjZBWWNQSzQyMTBFZGYwNm80Uno2V0NGaDA2LUFJOVZhY2xjX2tveGxiQmxka3JvV3gtZXg5ekY5b1NlSGhZMUZyNWJyeXJkM25lZ0lZRDlvaGwzVUQyT2Y5NFh2eEVRRWZ2dzlhYVdyRi16WklYV082Ti10ckdFSFJ3ZklxcFlQYzRSNW9oRUVRRDFFYXYyM0NTNUhsRWtDRHhnb2J2cXA3QmRhU3lZbEVpcF9JcUh3?oc=5" target="_blank">CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer
MedPage Todaygeneral

TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE0xTWVuYTM1QWlnYmpvYmVQQmtOc3h2NFY1MTVuS081Vkx2M09iQ0RXSm9famhLNWh1a2tWU2NiZEhDejRiWE9BdmMwRmN3VVJFQmlEWUE1eVE1VjlabVV5SUFSdG9FeTN5S1kwNUhRUUxiQjQyRHc?oc=5" target="_blank">TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
The OncFive: Top Oncology Articles for the Week of 6/21
OncLivegeneral

The OncFive: Top Oncology Articles for the Week of 6/21

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYXB6RlVzcFJSUTV5dFN5eHNTZ2xic3l0QjJIdlVIUmctU0xBSlpNekFpeDB1VnEwWGRjYTJxSGFsbkRTbnZFQml0elEyX3R3TGJwQ1Zpd2dZa0E1SS1jbEJhLUFnQjNiR1pyYUhUNFloTzkxb00tLTBVRU1LWkdKUkprUFI2aUpReTFR?oc=5" target="_blank">The OncFive: Top Oncology Articles for the Week of 6/21</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
Pharmacy Timesgeneral

FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPYWtITmM5WkoyU0xxaU1zS09LbTVpbjlGbWZ6bTFlbkpYeS0wOFlwa1gxZEw5MEJja1UwX0w5bFJPSDJULVdPSFQtdjFWaktRbGhVYTF5dVYzb01RUlRqcm96c2dTUXM3Qy1nWFFUNm1XY0wxblg5VkNIV2ZJS2NBSzY0d0ZWamFGR1NnS1Bmc0t1aXVPdm83WFVqQ3RyVnRzTldpZHlfeWtoQ1lIajJmMTBYMnNUUTdTenU4Nw?oc=5" target="_blank">FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast
Business Wiregeneral

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast

<a href="https://news.google.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?oc=5" target="_blank">FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer
OncLivegeneral

FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNak9Sdm9EWUY0LVkyUFc0NEpPWEdZU01YdkE1Zms4Y29CVnVYcXdXdHd6OURJdXJabEZMU09FOHBlNXhOR2VBcGV2S1VwdXlRVVR3V0FqMG5rMFZ3MVlnU0Y1c3J0SW1Nb3RCX3huRDZjMWowLTZIUmwwZTNGa1dTaHFidlBneUNkaHY5bXFBUHBNN0QycThNLTBST242X1llaXJwRGhrYjlxbTZ4ODc0Sw?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan-Hziy for HR+/HER2- Metastatic Breast Cancer
Oncology News Centralgeneral

FDA Approves Sacituzumab Govitecan-Hziy for HR+/HER2- Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWGYzbTN4d2tpbVF2QjRQTzNqSzY5X25zTjh1NEtiQmtMblZlSlUzZDY2SmNuQ0VONTJqMEIydmpTSEFXRlozc2haOE5YMk56eE9DSDgtbzFQX1U4MVNKc1E1QnZTdFRmTEJ6SHFTUlEzdFdCUkg2RE5MNzNRQkJGYmJDUXFVMlI5bWprLWN1NnJuWTlzNjJnMTJrWThUNnBDQmFZNjZPZzQzcHBsVlllN0lySWFNWnUtNnFF?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan-Hziy for HR+/HER2- Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
OncLivegeneral

FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQLW5VMFoyNkNwblpLUTRBb2VWdlFjM0tPWVpiNi0yd2d5VE1IaEFzN3lPc3JXSlpaV1pEOUpGaloycnowWTBBc2FlamExMF9oNkY5dllacFA1UDZFZENfUWZWb0g4RTFGU1VmVEZhSFFubU12M1cteEVtdnhQanBtSUQ1MTdOQnVRTzFiMm5TTS12Mm1FWnlKUzF3?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC
OncLivegeneral

FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQemh5OExWVWhGRE1nTWUyV05DdjlKQlE3YVB0YUg2NmZFRTlaN1RMd2dHQ3JXZURnZmYxcV9seE1UV2NBdjdlQVh0RHBORmRuVXBBZFd6UVJlN1EzdnNHb1p3TGdla2VWUmhveGIwNVAzVFlYWlRXVGlvRXdRM0hTYU1DcnFuQW41TjhYdWRWcFlwU2ky?oc=5" target="_blank">FDA Grants Regular Approval to Sacituzumab Govitecan for TNBC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status
CancerNetworkscience

Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOcWIzcUdOQjlHLWpkeXlwTHNHNGJJdTFTbzBHSHdsMVpJaG5wbGRvOUVWUFpaTkJJb1pnaU5RUXRRMUNDTVJnOFo2Yl85cnFLSU9udVJmNkVXNFVQNjl6cVRpbnRRTnp5N01GU2RPNWFRSHVUY0JZRGJwLVZTeW9CeUo2NkIyekdlS0hQZU5nVW1nM2ZBckxIbHFGa09kZHhZUnNadXhmVVhvLXVWRU5kd1daTXZMdw?oc=5" target="_blank">Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"FDA Approves Sacituzumab" — Live Google News Trends & Headlines